Equities researchers at Peel Hunt assumed coverage on shares of Abzena (LON:ABZA) in a research report issued on Thursday. The brokerage set a “buy” rating and a GBX 42 ($0.59) price target on the stock. Peel Hunt’s target price points to a potential upside of 64.58% from the stock’s current price.
ABZA has been the subject of a number of other research reports. Numis Securities restated a “buy” rating and set a GBX 80 ($1.12) price objective on shares of Abzena in a research note on Wednesday, December 13th. FinnCap reiterated a “buy” rating and issued a GBX 70 ($0.98) target price on shares of Abzena in a research report on Tuesday, November 21st.
Shares of Abzena (LON:ABZA) traded down GBX 0.48 ($0.01) during midday trading on Thursday, reaching GBX 25.52 ($0.36). The company’s stock had a trading volume of 10,341 shares, compared to its average volume of 48,482. Abzena has a 12-month low of GBX 25 ($0.35) and a 12-month high of GBX 53 ($0.74). The firm has a market cap of $54.57 and a price-to-earnings ratio of -319.00.
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.
Receive News & Ratings for Abzena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena and related companies with MarketBeat.com's FREE daily email newsletter.